内镜治疗原发性中枢神经系统淋巴瘤的疗效:一项多中心研究及文献综述
该回顾性多中心研究基于前瞻性构建的数据库,纳入欧洲10个中心的60例原发性中枢神经系统淋巴瘤患者,评估内镜治疗脑室内病变的疗效。结果显示内镜管理是有效选择,可作为获取活检、脑脊液分流及置入脑室通路装置的安全微创选项。
要点
- 内镜管理脑室内原发性中枢神经系统淋巴瘤是有效选择,作者认为可考虑为安全微创选项。
- 内镜可用于获取病变活检样本、通过第三脑室造瘘或脑室腹腔分流管理脑积水、置入脑室通路装置。
- 作者建议在仔细评估神经与免疫状态、替代诊断取样方案、病变位置及有无脑积水后再考虑内镜管理。
核心结论
- 作者认为内镜管理脑室内原发性中枢神经系统淋巴瘤是有效选择,可考虑为安全微创选项以获取活检、分流脑积水及置入脑室通路装置。
研究设计与样本
- 回顾性多中心研究,基于前瞻性构建的数据库,历时5年,涉及10个欧洲中心。
- 共纳入60例患者,女25例、男35例,平均年龄65.3岁,平均病灶大小40.3毫米。
主要发现
- 40例(66.6%)为脑室内浅表病变,其余20例(33.4%)病变累及或延伸至更深结构。
- 所有手术过程平稳,仅20/60例认为需要行内镜下第三脑室造瘘术(ETV)。
临床怎么用
- 作者认为内镜管理可作为获取病变活检样本的安全微创选项。
- 作者认为内镜管理可通过第三脑室造瘘或脑室腹腔分流进行脑脊液分流以管理脑积水。
- 作者认为内镜管理可置入脑室通路装置用于长期内科管理,并在需要时作为脑室穿刺的挽救选项。
- 作者建议在仔细评估神经与免疫状态、替代诊断取样方案、病变位置及有无脑积水后再考虑内镜管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To date, confined intra-ventricular localization of primary central nervous system lymphoma (PCNSL) has been usually managed with open surgical resection and/or stereotactic biopsy; nonetheless, the endoscopic approach to such localization can provide many advantages over standard microsurgery and/or stereotactic biopsy. Here we present our experience in managing such a rare pathology through the endoscopic approach. METHOD: In order to gather more information about such a rare pathology, a retrospective multicentric study on a prospectively built database has been performed during a 5 year period. Ten different European centers have been involved. RESULTS: A total of 60 patients, 25 women and 35 men, have been enrolled in the study. The mean age was 65.3 years. The mean lesion size was 40.3 mm. Among all selected patients, 40 (66.6%) had superficial lesions within the ventricle, whereas the remaining 20 (33.4%) had lesions involving/extending to deeper structures. All surgical procedures were uneventful and ETV was deemed necessary only in 20/60 cases. CONCLUSION: In our experience, endoscopic management of intraventricular PCNSL is an effective option. It should be considered after a careful examination of neurological and immunological status, alternative options for diagnostic sampling, location of the lesion, and presence or absence of hydrocephalus. Endoscopic management could be considered as a safe and minimally invasive option to obtain: (a) a biopsy sample of the lesion for further diagnostic workup, (b) CSF diversion through third ventriculostomy or VP shunt for the management of hydrocephalus, and (c) insertion of ventricular access devices for long term medical management and whenever necessary as a rescue option for ventricular tap.
引用
- Ganau M, Zaed I, Todeschi J, et al. Efficacy of endoscopic management of primary central nervous system lymphoma: a multicentric study and literature review. J Neurooncol. 2022. PMID: 35829848. doi:10.1007/s11060-022-04081-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。